BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst.

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the closing of its in vivo gene editing research collaboration and exclusive license agreement with Eli Lilly and Company following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended

Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 million Series B+ financing. The financing was co-led by RA Capital Management and Vivo Capital, wit

Cyclica announced the election of Sastry Chilukuri to its Board of Directors effective immediately. Chilukuri was also appointed to the Compensation and Governance sub-committees.

Temporomandibular joint (TMJ) implants are medical devices that are used to replace partial or the total jaw.

First and foremost, the rising awareness for proper disposal of medical waste is spelling growth in the medical waste containers market.

The platelet concentration systems market is expected to gain promising growth across the assessment period of 2020-2030.

Bayer has signed a collaboration and services agreement with CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid.

ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.